Harrow
Harrow's revenue rose 36.4% to $272 million in fiscal 2025. Its operating margin was 11.2%, up from 4.4% a year earlier. Free cash flow was $43 million. The diluted share count rose 3.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Harrow does
Harrow sells eye medicines in North America, mainly to eye doctors in the United States. Its products treat dry eye, wet age-related macular degeneration, cataracts, glaucoma, infections and other conditions of the front and back of the eye.
It has two kinds of products. The first is branded drugs approved by the US Food and Drug Administration, including IHEEZO for numbing the eye surface, VEVYE for dry eye, TRIESENCE, a steroid injection, and several eye drops it bought, such as VIGAMOX and ILEVRO. It also has two biosimilars, which are close copies of existing biologic drugs: BYOOVIZ, a copy of LUCENTIS, which it expects to launch in mid-2026, and OPUVIZ, a copy of EYLEA, expected in mid-2027. The second kind is compounded drugs, which its ImprimisRx pharmacies mix to a doctor's order. Compounded products are not FDA-approved themselves, though they use approved ingredients.
Harrow has grown its product list by acquisitions, licensing deals and its own development. It makes money by selling these products, and it depends on coverage and payment from government and private insurers. It also has outstanding notes due in 2030 and relies on outside companies to make some of its products.
Its biggest risks, as it describes them
- Achieving and keeping profitability while selling current, newly acquired and future products.
- Rules on compounded drugs and pharmacy licensing that could narrow its market or force facilities to close.
- Relying on third parties to make its products and run clinical trials.
- Insurers and government programs not paying enough for its products, and pressure on prices.
- Debt, including its 2030 Notes, and the need to access more capital.
Income statement
From fiscal 2018 to 2019, earnings per share fell 98.4% a year and net income 98.6% a year, as new shares raised the share count by 11% and diluted each share's earnings. Harrow then lost money in fiscal 2020, 2021, 2022, 2023, 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 51 | 102 | 83 | — | 73 |
| Debt incl. finance leases | 103 | 152 | 247 | 263 | 250 |
| Net debt (negative means net cash) | 52 | 50 | 164 | — | 177 |
| Net debt to EBITDA | 15.7x | 14.7x | 83.6x | — | 5.5x |
| Debt to equity | 9.1x | 5.5x | 3.5x | 3.8x | 4.8x |
| Interest coverage | 0.3x | 0.3x | 0.0x | 0.4x | 1.3x |
| Current ratio | 6.2x | 6.3x | 2.8x | 2.1x | 2.2x |
| Quick ratio | 5.8x | 6.0x | 2.6x | 2.0x | 2.1x |
Cash flow
Projections
Project Harrow's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Harrow says to expect
- Fourth quarter and full year 2026: adjusted EBITDA
We expect more than $33 million in fourth-quarter Adjusted EBITDA, bringing our full-year outlook to more than $40 million.
Insider trades
No officer, director or 10% owner of Harrow reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 3 of 9 | 6 of 9 |
| Rule of 40 | 48.8% | 41.4% | 52.2% |
| Altman Z'' | 0.81 | 0.77 | 1.29 |
| Accruals ratio | −12.0% | 1.4% | −12.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Fail | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | Pass | Pass | Pass |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Fail |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | 3 of 9 | 3 of 9 | 6 of 9 |
Compare
Put Harrow side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Harrow | FY25 | 36.4% | 11.2% | 15.8% | — | 5.5x | 6 | |
| Aurinia Pharmaceuticals | FY25 | 20.4% | 37.1% | 47.8% | — | — | — | Compare |
| Xeris Biopharma | FY25 | 43.7% | 8.5% | — | 19.6% | 4.2x | 7 | Compare |
| Rigel Pharmaceuticals | FY25 | 64.2% | 42.6% | — | 91.3% | −0.8x | 7 | Compare |
| Ironwood Pharmaceuticals | FY25 | −15.7% | 33.3% | 42.9% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 20 | 27 | 41 | 51 | 49 | 72 | 89 | 130 | 200 | 272 |
| Revenue growth | 105.2% | 34.3% | 54.5% | 23.7% | −4.5% | 48.3% | 22.2% | 47.0% | 53.3% | 36.4% |
| Gross profit | 10 | 13 | 25 | 34 | 34 | 54 | 63 | 91 | 150 | 204 |
| Research and development | 1 | 0 | 1 | 2 | 2 | 11 | 3 | 7 | 12 | 21 |
| Operating income | −16 | −12 | −5 | −5 | 0 | 2 | 2 | 0 | 9 | 30 |
| Net income | −19 | −12 | 15 | 0 | −3 | −18 | −14 | −24 | −18 | −5 |
| Diluted EPS (US$) | −1.50 | −0.60 | 0.61 | 0.01 | −0.13 | −0.69 | −0.51 | −0.75 | −0.49 | −0.14 |
| Diluted shares (millions) | 13 | 20 | 24 | 26 | 26 | 27 | 28 | 33 | 36 | 37 |
| Cash flow | ||||||||||
| Cash from operations | −11 | −9 | 1 | 1 | −1 | 5 | 2 | 4 | −22 | 44 |
| Capital expenditure | 7 | 1 | 2 | 2 | 1 | 2 | 3 | 2 | 2 | 1 |
| Free cash flow | −18 | −10 | −1 | −1 | −2 | 3 | −1 | 2 | −24 | 43 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 4 |
| Stock-based compensation | 4 | 3 | 2 | 2 | 3 | 6 | 8 | 16 | 18 | 12 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 9 | 4 | 7 | 5 | 4 | 51 | 102 | 83 | — | 73 |
| Debt incl. finance leases | 12 | 24 | 24 | 14 | 20 | 103 | 152 | 247 | 263 | 250 |
| Total assets | 27 | 24 | 50 | 59 | 58 | 98 | 157 | 312 | 389 | 400 |
| Total liabilities | 21 | 21 | 25 | 32 | 31 | 87 | 130 | 242 | 320 | 347 |
| Shareholders' equity | 6 | 3 | 25 | 28 | 27 | 11 | 28 | 71 | 70 | 52 |
| Margins and ratios | ||||||||||
| Gross margin | 50.7% | 49.6% | 60.1% | 67.3% | 70.4% | 74.9% | 71.3% | 69.5% | 75.3% | 75.0% |
| Operating margin | −79.6% | −45.4% | −12.6% | −9.4% | 0.8% | 2.2% | 2.2% | 0.3% | 4.4% | 11.2% |
| Net margin | −95.7% | −44.8% | 35.4% | 0.3% | −6.9% | −24.9% | −15.9% | −18.8% | −8.8% | −1.9% |
| Free cash flow margin | −90.8% | −35.8% | −2.6% | −1.0% | −4.0% | 4.5% | −1.0% | 1.8% | −11.9% | 15.8% |
| Rule of 40 (growth + FCF margin) | 14.5% | −1.5% | 51.9% | 22.7% | −8.5% | 52.9% | 21.2% | 48.8% | 41.4% | 52.2% |
| Return on capital | −182.4% | −60.9% | −13.0% | −9.7% | 0.8% | 2.4% | 2.2% | 0.2% | — | — |
| Return on equity | −756.4% | −264.9% | 106.9% | 0.6% | −12.2% | −93.6% | −72.5% | −49.6% | −24.9% | −8.4% |
| Return on assets | −92.3% | −46.9% | 39.9% | 0.3% | −5.8% | −23.1% | −11.0% | −10.4% | −5.0% | −1.3% |
| Net debt to EBITDA | — | — | — | — | 7.0x | 15.7x | 14.7x | 83.6x | — | 5.5x |